Propofol Manufacturer Ordered to Pay $365M in Nevada Hepatitis C Case, Plans Appeal
Teva, which was ordered to pay $365 million, said in a statement that the company clearly labeled the vials as single use and that aseptic procedures should be used at all times. The company believes there is enough evidence to warrant an appeal of the court's decision.
Baxter, which was ordered to pay $144 million, said it would also submit an appeal.
Mr. Chanin's case is the first of many to reach trial after a 2006 hepatitis C outbreak at Las Vegas endoscopy clinics. The $500 million award follows more than $5 million already awarded to Mr. Chanin and his wife by the same jury, according to the report.
Read the New York Times' report about the Las Vegas hepatitis C trial.
© Copyright ASC COMMUNICATIONS 2015. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
New From Becker's ASC Review
British Journal of Anaesthesia names Dr. Kane Pryor to associate editorial boardRead Now
- GI physician leader to know: Dr. Glenn Eisen of The Oregon Clinic
- 2 case studies highlight the need for effective infection control to prevent HCV transmissions
- 1st Navio-assisted SIGMA High Performance Unicondylar Knee surgery successful
- Survey: 67% of seniors want to access health services from home & 7 other key findings
- 15 things to know about ASC valuation from HealthCare Appraisers' 2015 Survey